We are excited to welcome Gimv as one of our new cornerstone investors. With the new shareholding structure BioConnection will be able to fund and further develop its human equity, infrastructure and service offering.
Alexander Willemse - CEO
BioConnection
BioConnection is a niche contract development and manufacturing organization (CDMO) focused on fill and finish and freeze-drying of injectable (bio)pharmaceutical products The company operates from its FDA & GMP approved manufacturing site in Oss (NL) and is one of the few niche players with both clinical and commercial manufacturing capabilities.
Share
2022
EUR 20 m
80
the Netherlands
When ambition meets ambition
The pharmaceutical industry is evolving towards targeted drug delivery platforms, complex molecules such as biologics and niche indications, all of which require a wider range of development capabilities and manufacturing capacity to ensure accelerated speed to market. To keep providing the highest service quality to its customers BioConnection foresees significant investments.
Gimv looks forward to supporting BioConnection in its next growth phase by further investing in the organisation and infrastructure to increase the production capacity and to further extend services to the customers.
Together, we build a leading company
We are very impressed by what Alexander and his team have built over the last decade. The quality of the facilities, the ability to serve and grow in the biotech sector and the contribution to the overall development in the pharma space (i.e. personalised medicine) is unparalleled in this size bracket. We are very much looking forward to supporting BioConnection through its next growth phase and continuing to build this already leading company.”
